TCR-T cells for EBV after stem cell transplant
Part of Infections clinical trials.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 75 years old.
- You have had a stem cell transplant for a blood cancer and now have an EBV infection.
- You are generally active and able to care for yourself (Karnofsky score 70+ or Lansky score 50+).
- You have a suitable donor whose immune cells match yours at least half (3 out of 6 HLA markers) and are in good health.
- You do not have severe graft-versus-host disease, serious organ problems, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
Hear when a new EBV Infection After Allogenic HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.